Article
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Haematologica - 1 Oct 2017
Daver Naval, Kantarjian Hagop, Garcia-Manero Guillermo, Jabbour Elias, Borthakur Gautam, Brandt Mark, Pierce Sherry, Vaughan Kenneth, Ning Jing, Nogueras González Graciela M, Patel Keyur, Jorgensen Jeffery, Pemmaraju Naveen, Kadia Tapan, Konopleva Marina, Andreeff Michael, DiNardo Courtney, Cortes Jorge, Ward Renee, Craig Adam, Ravandi Farhad
Abstract excerpt
Vosaroxin is an anti-cancer quinolone-derived DNA topoisomerase II inhibitor. We investigated vosaroxin with decitabine in patients ≥60 years of age with newly diagnosed acute myeloid leukemia (n=58) or myelodysplastic syndrome (≥10% blasts) (n=7) in a phase II non-randomized trial. The initial 22 patients received vosaroxin 90 mg/m2 on days 1 and 4 with decitabine 20 mg/m2 on days 1-5 every 4-6 weeks for up to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.